Saturday, December 22, 2018

‘Alarming’: Projected Burden of Liver Cancer in the US

Of Interest
Controlling the Global Burden of Liver Cancer
By Meg Barbor, MPH
December 25, 2018
According to Dr. Mohamed, target populations for hepatocellular carcinoma surveillance should include all patients with cirrhosis, regardless of etiology; patients with chronic HBV, particularly Asian men older than age 40 and women older than age 50; individuals with a family history of hepatocellular carcinoma; African and North American black individuals older than age 20 with HBV; and patients with noncirrhotic HCV and bridging fibrosis.
Read more:

‘Alarming’: Projected Burden of Liver Cancer in the US 
Roxanne Nelson, RN, BSN 
December 21, 2018
Follow On Twitter

The incidence of hepatocellular carcinoma in the US has been rapidly rising, but experts are cautiously optimistic that the trend can be reversed.

Over the past two decades, the incidence of hepatocellular carcinoma (HCC) has been steadily rising and is now a leading cause of cancer-related death in the United States. However, HCC disproportionally affects all US racial/ethnic minority populations, with blacks, Hispanics, and Asians experiencing higher age-specific incidence rates than non-Hispanic whites, according to an editorial in Journal of the National Cancer Institute (JNCI).

While incidence rates for HCC among most racial/ ethnic groups have steadily increased overall, the rates for blacks and Hispanics are projected to be the highest by 2030.

That said, even though the "projected burden of HCC in the United States is alarming, this future is not inevitable," write authors Amit G. Singal, MD and Caitlin C. Murphy, PhD, both of the University of Texas Southwestern Medical Center in Dallas.

They point to two studies recently published in the JNCI, which reviewed the racial/ethnic differences in incidence and projected future HCC burden. These two papers "paint a roadmap to reduce the increasing incidence and disparities in HCC in the United States," the editorialists comment.

No comments:

Post a Comment